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ABSTRACT
Background: Fluconazole (FLZ) is a drug commonly used for the treatment of Candida
infections. However, β-glucans in the extracellular matrices (ECMs) hinder FLZ penetration
into Candida biofilms, while extracellular DNA (eDNA) contributes to the biofilm architecture
and resistance.
Methods: This study characterized biofilms of FLZ-sensitive (S) and -resistant (R) Candida
albicans and Candida glabrata in the presence or absence of FLZ focusing on the ECM traits.
Biofilms of C. albicans American Type Culture Collection (ATCC) 90028 (CaS), C. albicans ATCC
96901 (CaR), C. glabrata ATCC 2001 (CgS), and C. glabrata ATCC 200918 (CgR) were grown in
RPMI medium with or without FLZ at 5× the minimum inhibitory concentration (37°C/48 h).
Biofilms were assessed by colony-forming unit (CFU)/mL, biomass, and ECM components
(alkali-soluble polysaccharides [ASP], water-soluble polysaccharides [WSP], eDNA, and pro-
teins). Scanning electron microscopy (SEM) was also performed. Data were analyzed by
parametric and nonparametric tests (α = 0.05).
Results: In biofilms, FLZ reduced the CFU/mL of all strains (p < 0.001), except for CaS
(p = 0.937). However, the ASP quantity in CaS was significantly reduced by FLZ (p = 0.034),
while the drug had no effect on the ASP levels in other strains (p > 0.05). Total biomasses and
WSP were significantly reduced by FLZ in the ECM of all yeasts (p < 0.001), but levels of eDNA
and proteins were unaffected (p > 0.05). FLZ affected the cell morphology and biofilm
structure by hindering hyphae formation in CaS and CaR biofilms, by decreasing the number
of cells in CgS and CgR biofilms, and by yielding sparsely spaced cell agglomerates on the
substrate.
Conclusion: FLZ impacts biofilms of C. albicans and C. glabrata as evident by reduced
biomass. This reduced biomass coincided with lowered cell numbers and quantity of WSPs.
Hyphal production by C. albicans was also reduced.
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Introduction
Candida species are commensal fungi of the oral
cavity of healthy individuals that can become oppor-
tunistic pathogens in some situations, for example,
when there are changes in the immune system, meta-
bolic dysfunction, or in the elderly population [1–7].
Moreover, increased use of broad-spectrum antibio-
tics, cytotoxic chemotherapies, and transplantation
also enhances the risk for infection by these oppor-
tunistic fungi [7]. These infections are known as
candidiasis. Candida albicans is the main species
associated with candidiasis, while Candida glabrata
is one of the most predominant non-albicans species
that has been linked to the development of oral
infections [1–6]. It is an opportunistic pathogen in
immunocompromised individuals [7,8], and it has an
innate resistance to azoles [9,10]. C. glabrata differs
from other pathogenic yeasts because of its
phylogenetic position and haploid state with uncon-
firmed sexual cycle and diploid phase, contrary to C.
albicans [11].
Candida infections are frequently related to the
establishment of biofilms. Biofilms are composed by
microbial cells that are attached to a substrate and
surrounded by an extracellular matrix (ECM) [12].
The ECM is composed of secreted microbial and
host-derived substances and cells lysis [12] and col-
laborates to the conservation of the biofilm architec-
ture and the preservation of stable interactions
between cell–cell, cell–surface, and the environment
[13]. Although polysaccharides and protein are the
most widely studied substances in biofilm ECMs,
other molecules, such as nucleic acids, are important
to their function [12].
Treatment of oral candidiasis includes the use of
topical [14] and systemic [15] antifungal medication,
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such as fluconazole (FLZ). Systemic antifungal med-
ication is usually prescribed for individuals with com-
promised overall health and those with recurrent
infections [15]. An important aspect to be considered
in therapy with topical or systemic antifungals is
resistance to these drugs. Resistance to antifungal
agents can be defined as the persistence or progres-
sion of infection after application of antimicrobial
treatment [16,17]. Some studies have observed the
emergence of resistant microorganisms during long-
term or prophylactic treatment [18,19]. Intrinsic or
primary resistance occurs when a microorganism has
low susceptibility to a medication, before its exposure
to the agent. Some Candida species possess intrinsic
resistance to antifungal drugs, especially to FLZ
[7,10]. In contrast, secondary resistance is one that
can be developed by yeasts after long periods of
exposure to antifungal drugs [16]. Thus, a major
concern with Candida spp. biofilms is that their
cells may have reduced susceptibility to azoles and
polyenes [20,21].
Antifungal resistance of Candida biofilms is multi-
factorial and involves the stimulation of drug efflux
pumps, the physiological state of cells, and the pro-
tection exerted by the ECM via β-glucans that bind to
FLZ and amphotericin B [22], which limits diffusion
of these antifungals through biofilms [23]. C. albicans
biofilms that grow under constant flow produce
higher quantities of ECM than statically cultured
biofilms. Importantly, the former also have increased
resistance to amphotericin B. This finding suggests
that ECM presence has an association with resistance
to amphotericin B in Candida species [24]. In the
same study, the authors detected that the ECM of C.
albicans GDH 2346 (NCYC 1467) contained carbo-
hydrate, protein, hexosamine, phosphorus, and uro-
nic acid. Nevertheless, the main constituent of the
ECM of C. albicans was glucose (32%) [24]. In addi-
tion to β-glucan, it has been reported that extracellu-
lar DNA (eDNA) is also an important ECM
constituent and one that promotes structural integrity
of candidal biofilms [25]. Furthermore, nuclear mag-
netic resonance investigation verified interaction of
ECM with FLZ, demonstrating a role in drug resis-
tance [26].
The difficulties in establishing what ECM compo-
nents are important in facilitating resistance to anti-
fungals have been a challenge [27]. As such,
enhanced knowledge of the assembly and function
of ECM will help inform the future design of more
effective therapies to control Candida pathogenesis
and biofilm development. Here, we characterized
the biofilms of FLZ-susceptible and -resistant C.
albicans and C. glabrata strains in the presence or
absence FLZ to evaluate the drug interference in the
ECM of these microorganisms.
Material and methods
Yeasts
Four American Type Culture Collection (ATCC)
Candida strains were used in this study: C. albicans
ATCC 90028 (FLZ-susceptible; CaS), C. albicans
ATCC 96901 (FLZ-resistant; CaR), C. glabrata
ATCC 2001 (FLZ-susceptible; CgS), and C. glabrata
ATCC 200918 (FLZ-resistant; CgR).
Growth curves
Growth curves were constructed based on optical den-
sity (OD) at 540 nm wavelength to ensure the repro-
ducibility of the biofilm model. Growth curves were
performed on three different occasions with three
replicates. The number of colony-forming units
(CFU) was determined at four-time points (Figure 1).
The microorganisms kept at −80°C were seeded
onto Petri dishes with Sabourand dextrose agar
(DIFCO, Detroit, MI) culture medium supplemented
with chloramphenicol (50 mg/L) [28] and incubated
at 37°C for 48 h. Then, five colonies of each micro-
organism were added separately to tubes containing
Yeast Nitrogen Base medium (YNB – DIFCO,
Detroit, MI) supplemented with 100 mM of glucose
[28] and these pre-inocula were incubated at 37°C for
16 h. Subsequently, the pre-inocula were diluted with
fresh YNB medium plus 100 mM glucose (1:20 dilu-
tion for C. albicans strains and 1:10 for C. glabrata
strains) to form the inocula, and the OD540 nm and
CFU were determined every 2 h in a total of 16 h for
each strain. Biofilms were generated using mid-log
growth phase cells (Figure 1).
Susceptibility testing and FLZ concentrations for
biofilm formation
The CLSI M27-A3 broth microdilution susceptibility
method [29] was performed with modifications to
examine the minimal inhibitory concentrations
(MICs) of FLZ against planktonic FLZ-susceptible
and -resistant C. albicans and C. glabrata strains.
FLZ powder (F8929, Sigma-Aldrich, St. Louis, MO)
was dissolved in sterile ultrapure water [30]. As a
positive control, a 100 µL of 2× concentrated RPMI
1640 buffered to pH 7.0 with 0.165 M (3-(N-mor-
pholino)propanesulfonic acid) (MOPS) plus a
100 µL of sterile ultrapure water was used (no cells
nor antifungal agent). As a negative control, only
cell suspensions were tested without the antifungal
agent. Serial twofold dilutions of FLZ (range: 0.125–
512 μg/mL) in RPMI 1640 medium buffered to pH
7.0 with 0.165 M of MOPS were inoculated in 96-
well plates with each microorganism suspension
adjusted to achieve a final inoculum concentration
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of 0.5 × 103–2.5 × 103 CFU/mL based on the growth
curves (Figure 1). The plates were incubated at 37°C
and observed for the presence or absence of growth
at 24 h. In addition to visual endpoint readings, the
OD of each plate well was measured at 562 nm after
24 h of incubation. MICs in spectrophotometer were
based on the density of the growth control and were
considered as the lowest drug concentrations that
resulted in minimum 90% decrease in growth
related to the drug-free growth control [31,32].
MICs were recorded in duplicate on three separate
occasions. As cells in biofilms are more resistant to
drugs [33], the concentrations of 5× and 10× were
tested during 48 h biofilm formation [34]. The 5×
MIC concentration was chosen because 10× MIC
almost completely inhibited the formation of biofilm
(data not shown), and this was not the goal of the
study since the inhibition of biofilm does not allow
the evaluation of FLZ effects on biofilms’ ECMs.
Thus, biofilms were generated in the presence of
FLZ at 5× MIC.
Biofilm formation and processing
Biofilm formation and processing for Log10 CFU/mL,
total biomass, insoluble biomass, proteins (from the
insoluble part of the biofilm and from the superna-
tant), alkali-soluble polysaccharide (ASP), water-solu-
ble polysaccharide (WSP), and eDNA were
performed according to the methodology described
by Panariello et al. [35]. Briefly, biofilms of CaS, CaR,
CgS, and CgR were developed for 48 h in RPMI
buffered with MOPS (pH 7.0). Biofilms (48 h) were
washed twice with 0.89% NaCl and detached by indi-
vidually scratching the wells with a pipette tip and
2 mL 0.89% NaCl. Then, biofilms were separated for
Log10 (CFU/mL) determination (0.1 mL) and for
total biomass determination [36] (0.1 mL). After
that, biofilms were vortexed, centrifuged (5,500×g/
10 min/4°C) and the supernatant containing the solu-
ble part of the matrix was separated from the pellet,
which contained the insoluble part of the matrix. The
supernatant was divided for the quantification of
WSPs (1 mL) [37], eDNA (0.650 mL) [38], and
matrix protein in the soluble portion (0.150 mL)
[39]. The pellet was washed twice and resuspended
in sterile ultrapure water; then, it was separated for
the quantification of insoluble biomass (0.8 mL), pro-
tein from the insoluble portion (0.05 mL) [39], and
ASPs (0.95 mL) [37].
Scanning electron microscopy
Biofilms were grown on polystyrene coupons placed
in 24-well culture plates [40]. Prior to use, coupons
were sterilized by microwave treatment for 3 min at
650 W [41] and dried in a flow chamber with UV
light for 30 min. After 48 h of biofilms growth, the
medium was removed, and the wells were washed
twice with 1 mL of sterile 0.89% NaCl. Next, the
biofilm samples were fixed with 2.5% glutaraldehyde
(60 min/room temperature), washed twice with ster-
ile 0.89% NaCl, and dehydrated. The dehydration
process was performed with series of washes with
ethanol 70 and 90% for 60 min each, followed by
five washes of 30 min with absolute ethanol. The
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Figure 1. Growth curves of (A) C. albicans ATCC 90028 (CaS), (B) C. albicans ATCC 96901 (CaR), (C) C. glabrata ATCC 2001 (CgS),
and (D) C. glabrata ATCC 200918 (CgR). In the mid-log phase, the mean ± standard deviation of OD540 nm for CaS is 0.55 ± 0.08
and the Log10 CFU/mL is 6.8 ± 0.1. For CaR, the OD540 nm is 0.39 ± 0.08 and the Log10 CFU/mL is 6.8 ± 0.3. For CgS, the OD540 nm
is 0.70 ± 0.08 and the Log10 CFU/mL is 7.4 ± 0.1. For CgR, the OD540 nm is 0.65 ± 0.09 and the Log10 CFU/mL is 7.6 ± 0.2.
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samples were stored in a desiccator with silica for
7 days to guarantee moisture-free samples. Then,
the samples were fixed in aluminum stubs, sputter
coated with gold, and observed with a JEOL JSM-
6610LV Scanning Electron Microscope, using magni-
fications of 160×, 600×, and 1,200×.
Statistical analyses
Normal distribution of data was verified by the
Shapiro–Wilk test and homogeneity of variance was
checked by the Levene test (α = 0.05). The quantita-
tive data of CFU/mL, biomass, proteins from the
insoluble portion and ECM components were statis-
tically analyzed by two-way analysis of variance
(ANOVA) considering the presence or absence of
FLZ and the different strains (CaS, CaR, CgS, CgS).
For multiple comparisons, the Tukey post hoc test
was applied for homoscedastic data and the Games-
Howell post hoc test for heteroscedastic data
(α = 0.05). When a postulation of normality was
not encountered, data were ranked and a nonpara-
metric analysis (ANOVA on ranks) was applied
(α = 0.05). The analyses were done in the software
SPSS (IBM® SPSS® Statistics, version 20, Chicago, IL).
Results
Susceptibility testing and FLZ concentrations for
biofilm formation
The MIC90 for planktonic cells were CaS = 16 µg/mL,
CaR = 256 µg/mL, CgS = 8 µg/mL, and
CgR = 256 µg/mL. However, the MIC90 concentra-
tion found for planktonic cells of CaS is not typical
for sensitive strains. As cited before, cells in biofilms
are more resistant than cells in planktonic cultures;
thus, for biofilm formation, 5× MIC was applied:
CaS = 80 µg/mL, CaR = 1,280 µg/mL, CgS = 40 µg/
mL, and CgR = 1,280 µg/mL.
Biofilm and ECM characterization
For Log10 (CFU/mL), there was a significant interac-
tion between the factors ‘FLZ’ and ‘strains’
(p < 0.001). FLZ significantly reduced (p < 0.001)
the Log10 (CFU/mL) values of CaR (reduction of
0.88 log), CgS (reduction of 0.71 log), and CgR
(reduction of 0.70 log). In contrast, the statistics
pointed out that the reduction of 0.67 log caused by
FLZ on CaS biofilms was not significant (p = 0.937).
Moreover, CaS presented the lowest CFU/mL of all
the strains in the absence of FLZ (p < 0.001). Mean
and standard deviations of Log10 (CFU/mL) are
represented in Figure 2.
The total biomass analysis showed that the factor
‘FLZ’ significantly interacted with the results
(p < 0.001), reducing the biomasses of all the strains
(Figure 3). For the insoluble biomass, data pointed to
an interaction between the factors ‘FLZ’ and ‘strains’
(p < 0.001). The presence of FLZ significantly
reduced the insoluble biomass of CaS (p = 0.038),
CaR (p < 0.001), and CgR (p < 0.001). In contrast,
CgS showed higher insoluble biomass in the presence
of FLZ when compared to CgS in the absence of FLZ
(p < 0.001). Mean and standard deviations of insolu-
ble biomasses are given in Figure 4.
For WSP data, the analysis showed that the only
factor that influenced the quantity of WSP was ‘FLZ’
(p < 0.001), reducing this component in the ECM of
all the evaluated strains (Figure 5). For ASP data, a
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Figure 2. Mean values and standard deviations of Log10 (CFU/mL) of CaS, CaR, CgS, and CgR in the absence (white bars) or in
the presence (gray bars) of fluconazole (FLZ). Bar charts were applied for normal data submitted to parametric analysis (ANOVA).
Equal letters designate statistical correspondence (p < 0.05).
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significant interaction between the factors ‘FLZ’ and
‘strains’ (p = 0.002) was found. Statistics demon-
strated that FLZ significantly reduced the ASP
amount in CaS (p = 0.034). However, for the other
strains, FLZ did not alter the ASP amounts
(p > 0.200). Moreover, CgS produced significantly
smaller amounts of ASP than the other evaluated
strains (p = 0.008). Mean and standard deviations of
ASP are presented in Figure 6.
Two-way analysis for matrix protein data showed
that the factor 'strain' was significant (p<
0.001). However, post hoc tests showed no statistical
differences in the quantity of matrix proteins between
the strains in the presence or the absence of FLZ
(p > 0.05) (Figure 7). Protein data from the insoluble
portion showed that there was no significance of factors
‘FLZ’ (p = 0.124), ‘strain’ (p = 0.124), and the interaction
between ‘FLZ’ and ‘strain’ (p = 0.573). Thus, no post-hoc
tests were performed. Consequently, protein amounts
from the insoluble portion were not affected by FLZ,
and the type of the strain did not influence the quan-
tities of this component.
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Figure 3. Box-plot of total biomass (mg) without (white bar)
and with FLZ (gray bar). The box-plot shows the median
(dash), the first and third quartiles (outer edges of box),
and the highest and maximum values (error bars). A non-
parametric analysis (ANOVA on rank) was applied. Equal
letters designate statistical correspondence (p > 0.05).
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Figure 4. Box-plot of insoluble biomass (mg) in CaS, CaR,
CgS, and CgR in the absence (white boxes) or in the presence
(gray boxes) of FLZ. The box-plot shows the median (dash),
the first and third quartiles (outer edges of box), and the
highest and maximum values (error bars). A nonparametric
analysis (ANOVA on rank) was applied. Equal letters designate
statistical correspondence (p > 0.05).
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Figure 5. Box-plot of water-soluble polysaccharides-WSP
amounts (μg) without (white bar) and with FLZ (gray bar).
The box-plot shows the median (dash), the first and third
quartiles (outer edges of box), and the highest and maximum
values (error bars). A nonparametric analysis (ANOVA on rank)
was applied. Equal letters designate statistical correspon-
dence (p > 0.05).
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Figure 6. Box-plot of alkali-soluble polysaccharides-ASP
amounts (μg) in CaS, CaR, CgS, and CgR in the absence
(white boxes) or in the presence (gray boxes) of FLZ. The
box-plot shows the median (dash), the first and third quar-
tiles (outer edges of box), and the highest and maximum
values (error bars). A nonparametric analysis (ANOVA on rank)
was applied. Equal letters designate statistical correspon-
dence (p < 0.05).
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Figure 7. Box-plot of matrix protein amounts (μg) in CaS, CaR,
CgS, and CgR in the absence (white boxes) or in the presence
(gray boxes) of FLZ. The box-plot shows the median (dash),
the first and third quartiles (outer edges of box), and the
highest and maximum values (error bars). A nonparametric
analysis (ANOVA on rank) was applied. Equal letters designate
statistical correspondence (p < 0.05).
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For eDNA, data revealed that there was no signifi-
cance of the factors ‘FLZ’ (p = 0.936), ‘strain’
(p = 0.431), and between the factors ‘FLZ’ and
‘strains’ (p = 0.974). Therefore, eDNA quantities
were not affected by FLZ and were the same inde-
pendent of the type strain. As there was no statistical
significance of any factor or interaction for protein
from the insoluble portion and for the eDNA data,
mean and standard deviations from the quantifica-
tion of these components are shown in Table 1.
Biofilm structure
Scanning electron microscopy (SEM) was performed
to examine the overall biofilm structure of the differ-
ent yeasts in the presence and absence of FLZ. Special
attention was given to cell morphology and spatial
organization on the substrate, as well as on ECM
covering and/or linking cells in these biofilms.
Figure 8 shows the SEM images of CaS (Figure 8
(A–C)) and CaS + FLZ (Figure 8(D–F)), demonstrat-
ing that FLZ reduced the size of hyphae. A closer look
at the structures shows that, without FLZ, cells were
embedded in the ECM, as shown by the arrow
(Figure 8(C)).
Figure 9 shows the SEM images of biofilms formed
by CaR (Figure 9(A–C)) and CaR + FLZ (Figure 9(D–
Table 1. Proteins from the insoluble portion (µg) and eDNA
(µg) in sensitive and resistant C. albicans and C. glabrata to
fluconazole (FLZ).
Proteins from the insoluble portion (µg) eDNA (µg)
CaS 1.16 28.32
(0.77) (8.65)
CaR 1.35 34.98
(1.07) (16.50)
CgS 1.25 25.41
(0.96) (11.36)
CgR 1.52 25.59
(0.74) (10.76)
CaS + FLZ 1.16 36.14
(0.23) (8.72)
CaR + FLZ 1.29 28.27
(0.47) (10.94)
CgS + FLZ 1.07 28.39
(0.33) (11.53)
CgR + FLZ 1.29 20.97
(0.47) (6.58)
Two-way ANOVA revealed that there was no significance of the factors
‘FLZ’, ‘strain’, and between the factors ‘FLZ’ and strains for protein and
eDNA, meaning there was no statistical difference between the condi-
tions depicted for each of the components.
a d
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Figure 8. Scanning electron microscopy (SEM) images of CaS (A,B,C) and CaS + FLZ (D,E,F). FLZ (80 µg/mL) reduced the size of
the hyphae (D,E,F). A closer look at the cells structures shows that without FLZ, it is possible to see the cells embedded in the
ECM, as shown by the arrow (C).
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F)). The CaR biofilm possessed large amounts of
yeast cells and elongated hyphae structures (Figure 9
(A–C)). Figure 9(C) shows the union of cells within
biofilms through their ECMs, as exemplified by the
arrow. FLZ reduced the size and number of hyphae;
remaining cells were mostly cells with yeast morphol-
ogy (Figure 9(C–E)).
Figure 10 shows the SEM images of biofilms
formed by CgS (Figure 10(A,B)) and CgS + FLZ
(Figure 10(C,D)). The CgS biofilm was composed of
yeast cells (Figure 10(A)) linked by ECM (Figure 10
(B)). The presence of FLZ reduced the number of
cells (Figure 10(C)) and the ECM (Figure 10(D)).
Figure 11 shows the SEM images of biofilms
formed by CgR (Figure 11(A,B)) and CgR + FLZ
(Figure 11(C,D)). The CgR biofilm presented a high
quantity of yeast cells (Figure 11(A)) and clusters
interconnected by ECM (Figure 11(B)). The presence
of FLZ reduced the number of cells (Figure 11(C))
and the ECM (Figure 11(D)).
Discussion
FLZ is often a chosen treatment for Candida infec-
tions because of its low cost and availability for oral
administration [42]. This drug prevents the biosynth-
esis of ergosterol through the cytochrome P450
enzyme 14-α demethylase, which catalyzes the con-
version of lanosterol to ergosterol [43]. The reduction
of ergosterol changes the fluidity of the membrane
and the activity of numerous membrane-bound
enzymes, hindering fungal growth and replication
[43]. However, FLZ-resistance is rising in Candida
species [42,44,45,46], requiring a better understand-
ing of the action of this drug in Candida biofilms.
Due to the mechanism of action of FLZ, variations in
the architecture of the ECM may happen during
Candida biofilm formation in presence of this med-
ication [34,47]. Here, we characterized the biofilms
formed by FLZ-susceptible and -resistant C. albicans
and C. glabrata strains in presence or absence FLZ to
evaluate the drug interference in the ECM of these
microorganisms.
Surprisingly, no significant reduction in CaS
counts was observed after exposure to 5× MIC
doses of FLZ (Figure 2), and the images showed
that FLZ reduced the size of hyphae in the strain
(Figure 8(C–E)). However, the growth of CaR bio-
films in the presence or absence of FLZ showed that
the drug significantly reduced its population
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CaR CaR+FLZ
Figure 9. SEM images of CaR (A,B,C) and CaR + FLZ (D,E,F). The CaR biofilm possesses large amounts of yeast cells and
elongated hyphae structures (B,C). Image C shows the union of cells within biofilms through their extracellular matrices, as
exemplified by the arrow. FLZ (1,280 µg/mL) reduced the number and size of hyphae, remaining mostly yeast cells (D,E,F).
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(Log10 CFU/mL) (Figure 2). In addition, SEM
images showed that FLZ reduced hyphae formation
in CaR (Figure 9(D–F)). This result corroborated a
previous study that observed that FLZ has a direct
inhibitory effect on hyphal formation [48]. Since
FLZ interferes with the ergosterol pathway and
ergosterol is necessary for hyphae formation, the
presence of FLZ inhibits the transition from yeast
to hypha [48], even in a culture medium that pro-
motes C. albicans filamentous morphology. Thus,
taking into consideration that hypha is the invasive
form of C. albicans [49], the reduction of its size in
CgS CgS+FLZ
d
a
b
c
Figure 10. SEM images of CgS (A,B) and CgS + FLZ (C,D). CgS biofilm is composed by yeast cells (A) linked by ECM (B). The
presence of FLZ (40 µg/mL) reduced the number of cells (C) and the ECM (D).
CgR CgR+FLZ
a c
b d
Figure 11. SEM images of CgR (A,B) and CgR + FLZ (C,D). CgR biofilm presents a high-quantity yeast cells (A) and clusters
interconnected by ECM, exemplified by arrows (B). The presence of FLZ (1,280 µg/mL) reduced the number of cells (C) and the
ECM (D).
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both CaS and CaR is an important result in the
decrease of the virulence of this strain. In addition,
FLZ significantly reduced the CFU/mL in CgS and
CgR (Figure 2). These results were confirmed by the
SEM images of CgS (Figure 10(D,E)) and CgR
(Figure 11(D,E)), which showed that fewer cells
and cell agglomerates were more sparsely distributed
on the substrate. It has been reported that C. glab-
rata has a decreased intrinsic susceptibility to FLZ
and other classes of azole antifungals [42,50,51].
Nevertheless, the results of the present study showed
that biofilm formation with 40 µg/mL of FLZ for
CgS and 1,280 µg/mL of FLZ for CgR can reduce the
cell viability of these microorganisms. Therefore, the
log reduction values for all strains were very close
(CaS: reduction of 0.67 log, CaR: reduction of
0.88 log, CgS: reduction of 0.71 log, and CgR: reduc-
tion of 0.70 log).
An important finding of this study was that FLZ
acted on the ECM of all the yeasts by reducing the
production of WSPs (Figure 5). Candida biofilm
matrix has α-1,2 branched and α-1,6 mannans
(WSPs) associated with β-1,6 glucans (ASPs), consti-
tuting a mannan–glucan complex (MGCx) [26].
Considering that interactions of ECM polysacchar-
ides are required for biofilm antifungal resistance
[52], the reduction on WSP amounts in the ECM of
the biofilms in the presence of FLZ might alter the
constitution of the MGCx, leading to a higher sus-
ceptibility of the biofilms to antifungal therapy.
Another notable finding of this study was that FLZ
caused an important antibiofilm activity by causing a
significant reduction in the total biomasses of all the
yeasts studied. Cells and ECM components compose
the biomasses. Thus, the significant reduction of the
biomasses could have occurred because of the
decrease of WSP, the reduction of the hyphae size
in CaS (Figure 8(D–F)) and CaR (Figure 9(D–F)),
and the decrease in cells in CgS (Figure 10(C,D))
and CgR (Figure 11(C,D)).
In addition, FLZ significantly reduced the ASPs
content only in the ECM of the CaS strain biofilm
(Figure 6). The ASPs, such as β-1,3 glucans, seques-
trate antifungals preventing them from diffusing
through the ECMs of C. albicans [22,52–55] and
non-albicans biofilms [56]. It has been demonstrated
that β-1,3 glucan has a role in antifungal resistance as
it binds to FLZ avoiding this drug to reach its targets
[22,52–56]. Thus, ASP’s significant reduction in the
ECM of CaS biofilms demonstrates that the biofilms
of this specific strain become more vulnerable when
FLZ is present. Moreover, although ASPs can bind to
FLZ, when 80 μg/mL of FLZ is present during CaS
biofilm formation, the drug can evade this effect and
cause ASP reduction.
The insoluble content of the biofilm (i.e. ASP and
cells, which contain the proteins) constitutes the
insoluble biomass. The results showed that in the
presence of FLZ, there was a significant reduction in
the insoluble biomass of CaS, CaR, and CgR
(Figure 4) probably caused by the reduction of
hyphae and blastopores, and by the numerical
decrease in the ASP content. However, CgS showed
a significant increase in the insoluble biomass in
presence of FLZ. Variations in the ECM might hap-
pen when ions are available [57]. Possibly, ions from
FLZ (C13H12F2N6O) might have interacted with car-
boxylic acid groups of the matrix to produce grids of
macromolecules with higher viscosity resulting in a
stickier polysaccharide matrix [57].
FLZ caused no effects on eDNA, proteins (from the
insoluble part of the biofilm), and matrix protein
amounts in all the strains evaluated. The production
of eDNA has been associated to hyphal growth [58].
Nevertheless, the present study demonstrated that
even in the absence of hyphae (e.g. in C. glabrata
biofilms), all biofilms released comparable amounts
of eDNA both in presence or absence of FLZ. This
result corroborates to a previous finding that observed
that a strain defective in hyphae formation (Δ/Δ efg1)
was capable of producing eDNA similar to its parental
strains that formed hyphae [35]. In C. albicans, eDNA
contributes to the preservation and stability of mature
biofilms, but not to their establishment [24,25], while
the recognized role of some proteins is linked to
metabolism [26]. In addition, eDNA performs as a
regulator of biofilm cell antifungal resistance against
echinocandins and amphotericin B but does not seem
to significantly contribute to FLZ resistance [59]. This
finding corroborates with the results found here, since
FLZ did neither affect the production of eDNA nor the
production of proteins.
The present study showed that WSPs and bio-
masses are directly affected by the presence of FLZ
during biofilm formation in the FLZ-susceptible and
-resistant C. albicans and C. glabrata strains studied,
while eDNA and proteins were not altered by the
presence of FLZ, independent of the strain. Thus,
FLZ impacts biofilms of C. albicans and C. glabrata
as evident by reduced biomass. The reduced biomass
coincided with lowered cell numbers and the quantity
of WSPs. Hyphal production by C. albicans was also
reduced. The reduction of WSP and total biomasses
may be related to biofilms susceptibility to therapeu-
tics and virulence, making those growing in FLZ
more susceptible and potentially less virulent.
However, as FLZ is fungistatic, there is a chance for
the development of acquired resistance during the
treatment with this antifungal agent [46]. Moreover,
5× MIC concentrations of the drug during biofilm
formation did not affect eDNA and proteins.
Therefore, it is important to consider alternative
ways to disorganize the ECMs to get a better diffusion
of the drug through the biofilms to reach the cells.
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